Ribociclib (brand name Kisqali) side effects most commonly fall into a few buckets: hematologic (blood counts), GI, fatigue, and electrolyte/QT-related effects.
Most common side effects (as reported across clinical use)
1) Blood count effects
- Neutropenia (low neutrophils)
- Leukopenia (low white blood cells)
- Anemia (low hemoglobin)
- Thrombocytopenia (low platelets)
(These are among the most clinically important because they can drive dose holds/reductions and monitoring.)
2) Gastrointestinal
- Nausea
- Diarrhea
- Vomiting
- Stomatitis / oral inflammation (e.g., mouth sores)
3) General / systemic
- Fatigue / asthenia
- Decreased appetite
4) Infectious/fever-related (often secondary to neutropenia)
- Infections (including febrile neutropenia in some patients)
5) Cardiac / ECG-related (important, though not always the “most common”)
- QT interval prolongation (requires ECG and electrolyte monitoring)
- Bradycardia can occur
6) Liver enzyme changes
- Increased transaminases (ALT/AST elevations)
- Increased bilirubin (less common than transaminase elevations)
Practical note for HTA/payer audiences
While “most common” usually emphasizes nausea, diarrhea, fatigue, and neutropenia, QT prolongation and liver enzyme elevations are key adverse events for clinical management and therefore often highlighted even when incidence is lower than hematologic events.
If you tell me whether you want (a) the top 5 adverse events with approximate incidence from a specific label/source (FDA vs EMA vs trial publication) and in (b) the population (HR+/HER2− advanced/metastatic breast cancer; combination with aromatase inhibitor vs fulvestrant), I can format it in a way that’s ready for an HTA evidence table.